{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:34Z","timestamp":1793225974566,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jhep.2024.01.028","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T09:03:17Z","timestamp":1707296597000},"page":"792-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Increased Siglec-9\/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy"],"prefix":"10.1016","volume":"80","author":[{"given":"Rong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6084-8993","authenticated-orcid":false,"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5798-2274","authenticated-orcid":false,"given":"Chunyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuanchang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-2214","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-4718","authenticated-orcid":false,"given":"Chunhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jhep.2024.01.028_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.01.028_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.semcancer.2022.01.005","article-title":"Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data","volume":"86","author":"Harkus","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jhep.2024.01.028_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/OTT.S333233","article-title":"The research progress of bufalin in the treatment of hepatocellular carcinoma","volume":"15","author":"Jiang","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jhep.2024.01.028_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/gutjnl-2011-300509","article-title":"Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma","volume":"61","author":"Chew","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.01.028_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clim.2008.08.012","article-title":"Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients","volume":"129","author":"Cai","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/cmi.2014.91","article-title":"NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma","volume":"12","author":"Sun","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2024.01.028_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.01.028_bib9","article-title":"Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant","volume":"8","author":"Anugwom","year":"2022","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jhep.2024.01.028_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.01.028_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.01.028_bib12","doi-asserted-by":"crossref","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2024.01.028_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2024.01.028_bib14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.01.028_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.01.028_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhep.2024.01.028_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"RodrIguez","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2024.01.028_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/bmm-2016-0284","article-title":"Glycosylation change of alpha-1-acid glycoprotein as a serum biomarker for hepatocellular carcinoma and cirrhosis","volume":"11","author":"Zhang","year":"2017","journal-title":"Biomark Med"},{"key":"10.1016\/j.jhep.2024.01.028_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.it.2020.02.001","article-title":"Sialoglycans and siglecs can shape the tumor immune microenvironment","volume":"41","author":"van de Wall","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib21","doi-asserted-by":"crossref","first-page":"790317","DOI":"10.3389\/fimmu.2021.790317","article-title":"Siglec signaling in the tumor microenvironment","volume":"12","author":"van Houtum","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","article-title":"Siglecs as immune cell checkpoints in disease","volume":"38","author":"Duan","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib24","first-page":"118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2024.01.028_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cei.13444","article-title":"Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma","volume":"201","author":"Tao","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib26","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2018.01124","article-title":"Decreased siglec-9 expression on natural killer cell subset associated with persistent HBV replication","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib27","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses","volume":"6","author":"Daly","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jhep.2024.01.028_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1476-4598-9-118","article-title":"Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes","volume":"9","author":"Belisle","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhep.2024.01.028_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.778989","article-title":"Development of siglec-9 blocking antibody to enhance anti-tumor immunity","volume":"11","author":"Choi","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2024.01.028_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nchembio.1388","article-title":"Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion","volume":"10","author":"Hudak","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jhep.2024.01.028_bib31","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2024.01.028_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.743515","article-title":"Siglec-9, a putative immune checkpoint marker for cancer progression across multiple cancer types","volume":"9","author":"Wu","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jhep.2024.01.028_bib35","doi-asserted-by":"crossref","first-page":"22127","DOI":"10.1074\/jbc.M002775200","article-title":"Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways","volume":"275","author":"Angata","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2024.01.028_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/BJ20060103","article-title":"The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design","volume":"397","author":"Attrill","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2024.01.028_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J\u00a0Comput Chem"},{"key":"10.1016\/j.jhep.2024.01.028_bib38","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.01.028_bib39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jhep.2015.05.019","article-title":"Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?","volume":"63","author":"Wong","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.01.028_bib40","doi-asserted-by":"crossref","first-page":"104992","DOI":"10.1016\/j.phrs.2020.104992","article-title":"HBV induced hepatocellular carcinoma and related potential immunotherapy","volume":"159","author":"Jia","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhep.2024.01.028_bib41","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.01.028_bib42","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2024.01.028_bib43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s13238-018-0597-5","article-title":"Sialylation is involved in cell fate decision during development, reprogramming and cancer progression","volume":"10","author":"Li","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.jhep.2024.01.028_bib44","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.01.028_bib45","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2024.01.028_bib46","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1172\/JCI65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2024.01.028_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6243819","article-title":"The roles of Siglec7 and Siglec9 on natural killer cells in virus infection and tumour progression","volume":"2020","author":"Zheng","year":"2020","journal-title":"J Immunol Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:22:51Z","timestamp":1713324171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0168827824001065"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Siglec-9\/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}